BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trialWeijia Wang, Yong Yuan, Min Wang et al.|Annals of the Rheumatic Diseases|2024Cited by 194
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignanciesKevin H. Chen, Yupo Ma|Oncotarget|2016Cited by 112
Stem Cell Gene SALL4 Suppresses Transcription through Recruitment of DNA MethyltransferasesJianchang Yang, Yupo Ma|Journal of Biological Chemistry|2011Cited by 71
Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4Jianchang Yang, Yupo Ma|Journal of Hematology & Oncology|2011Cited by 57
Validation of BCMA-CD19 Compound CAR-T Therapy in SLE Overlap Syndrome: Over 1.5-Year Follow-UpMin Wang, Weijia Wang, V. Destéfano et al.|Stem Cell Reviews and Reports|2025Cited by 9